Simulations Plus (NASDAQ:SLP) Upgraded to Strong-Buy by ValuEngine

ValuEngine upgraded shares of Simulations Plus (NASDAQ:SLP) from a buy rating to a strong-buy rating in a research report report published on Friday, ValuEngine reports.

Several other brokerages also recently weighed in on SLP. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, May 11th. BidaskClub downgraded Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 9th.

Shares of NASDAQ SLP opened at $31.91 on Friday. The firm has a fifty day moving average price of $27.62. Simulations Plus has a one year low of $17.10 and a one year high of $32.85. The firm has a market cap of $559.41 million, a price-to-earnings ratio of 63.82 and a beta of -0.39.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, July 10th. The technology company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. The firm had revenue of $9.94 million for the quarter, compared to analyst estimates of $9.85 million. On average, sell-side analysts forecast that Simulations Plus will post 0.44 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Thursday, July 25th will be paid a $0.06 dividend. The ex-dividend date is Wednesday, July 24th. This represents a $0.24 annualized dividend and a dividend yield of 0.75%. Simulations Plus’s payout ratio is 48.00%.

In other news, Director Walter S. Woltosz sold 18,500 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total value of $474,895.00. Following the completion of the sale, the director now owns 5,178,083 shares of the company’s stock, valued at $132,921,390.61. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 31.57% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its stake in Simulations Plus by 156.9% in the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after acquiring an additional 1,290 shares during the period. BNP Paribas Arbitrage SA grew its stake in Simulations Plus by 59,875.0% in the first quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock valued at $51,000 after acquiring an additional 2,395 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in Simulations Plus in the fourth quarter valued at approximately $79,000. MetLife Investment Advisors LLC acquired a new stake in Simulations Plus in the fourth quarter valued at approximately $108,000. Finally, Bank of America Corp DE grew its stake in Simulations Plus by 65.7% in the fourth quarter. Bank of America Corp DE now owns 8,754 shares of the technology company’s stock valued at $174,000 after acquiring an additional 3,471 shares during the period. 41.25% of the stock is owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

See Also: What is an Initial Public Offering (IPO)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit